论文部分内容阅读
目的比较门冬胰岛素30和精蛋白生物合成人胰岛素30R治疗2型糖尿病的经济性,为临床用药选择、药品定价等相关决策提供参考。方法采用二次文献研究,搜集国内外已发表的关于门冬胰岛素30和精蛋白生物合成人胰岛素30R治疗2型糖尿病的有效性的相关文献,并进行汇总、筛选,利用Revman5.2软件对所提取的有效性数据进行Meta分析,在此基础上,对门冬胰岛素30和精蛋白生物合成人胰岛素30R进行成本-效果分析,并进行敏感性分析。结果门冬胰岛素30组和精蛋白生物合成人胰岛素30R组总成本分别为1 665.44元和1 383.86元,Hb A1c分别降低2.46和1.83个单位;针对文献质量、药品价格、疗程、使用剂量及检查成本进行的敏感性分析显示这一结果稳定。结论门冬胰岛素30治疗2型糖尿病的经济性总体上优于精蛋白生物合成人胰岛素30R,更具有临床推广价值,但还需进一步深入研究。
Objective To compare the economic efficiency of aspart insulin 30 and protamine biosynthesis human insulin 30R in the treatment of type 2 diabetes mellitus, and to provide references for clinical drug selection, drug pricing and other related decisions. Methods A literature review was conducted to collect the published literatures about the effectiveness of insulin aspart 30 and protamine biosynthetic human insulin 30R in the treatment of type 2 diabetes at home and abroad. The data were summarized and screened. Meta-analysis was conducted on the validity data extracted. Based on this, the cost-effectiveness analysis was conducted on aspart insulin 30 and protamine biosynthetic human insulin 30R and sensitivity analysis was performed. Results The total costs of insulin aspart 30 and protamine biosynthetic human insulin 30R were 1 665.44 yuan and 1 383.86 yuan, respectively, while Hb A1c was 2.46 and 1.83 lower respectively. According to the quality of the literature, the price of medications, the course of treatment, the dosage and examination Sensitivity analysis of costs shows that this result is stable. Conclusion Aspartic insulin 30 is generally superior to protamine biosynthesis human insulin 30R in the treatment of type 2 diabetes, which is more valuable for clinical promotion. However, further study is needed.